Breast carcinomas with hyperprolactinemia at the time of diagnosis-clinico-biological association

References

• Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010;206:1–11.
   PubMed Web of Science ®Google Scholar
• Fernandez I, Touraine P, Goffin V. Prolactin and human tumourogenesis. J Neuroendocrinol 2010;22:771–777.
   PubMedGoogle Scholar
• Boutin JM, Jolicoeur C, Okamura H, Gagnon J, Edery M, Shirota M, Banville D, et al. Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family. Cell 1988;53:69–77.
   PubMed Web of Science ®Google Scholar
• Leung DW, Steven A, Spencer George, Cachianes, Glenn Hammonds R, Carol Collins, William J, Henzel Ross, Barnard, et al. Growth hormone receptor and serum binding protein: Purification, cloning and expression. Nature 1987;330:537–543.
   PubMed Web of Science ®Google Scholar
• Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci USA 1989;86:8083–8087.
   PubMed Web of Science ®Google Scholar
• Jacobson EM, Hugo ER, Tuttle TR, Papoian R, Ben-Jonathan N. Unexploited therapies in breast and prostate cancer: Blockade of the prolactin receptor. Trends Endocrinol Metab 2010;21:691–698.
   PubMed Web of Science ®Google Scholar
• Ben–Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metabol 2002;13:245–250.
   PubMed Web of Science ®Google Scholar
• Galbaugh T, Feeney YB, Clevenger CV. Prolactin receptor-integrin cross-talk mediated by SIRPa in breast cancer cells. Mol Cancer Res 2010;8:1413–1424.
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett 2006;243:160–169.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang K, Chen KE, Walker AM. Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor-α in T47D breast cancer cells. Breast Cancer Res Treat 2010;120:369–377.
   Google Scholar
• González L, Zambrano A, Lazaro-Trueba I, Lopéz E, González JJ, Martín-Pérez J, Aranda A. Activation of the unliganded estrogen receptor by prolactin in breast cancer cells. Oncogene 2009;28:1298–1308.
   PubMed Web of Science ®Google Scholar
• Corbacho AM, Martínez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 2002;173:219–238.
   PubMed Web of Science ®Google Scholar
• Wang DY, Stepniewska KA, Allen DS, Fentiman IS, Bulbrook RD, Kwa HG, De Stavola BL, Reed MJ. Serum prolactin levels and their relationship to survival in women with operable breast cancer. J Clin Epidemiol 1995;48:959–968.
   Google Scholar
• Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, et al. Serum prolactin levels in womemn with breast cancer and their relationship to survival. Eur J Cancer Clinical Oncology 1986;22:487–492.
   PubMedGoogle Scholar
• Holtkamp W, von Heyden D, Rauschecker H, Nagel GA. Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors. Schweiz Med Wochenschr 1983;113:1513–1520.
   Google Scholar
• Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 1984;34:323–328.
   PubMedGoogle Scholar
• Robin C. Prolactin and breast cancer. Pathol Biol 1975;23:783–792.
   Google Scholar
• Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 2010;13:195–198.
   PubMed Web of Science ®Google Scholar
• Goodman G, Bercovich D. Prolactin does not cause breast cancer and may prevent it or be therapeutic in some conditions. Medical Hypotheses 2008;70:244–251.
   Google Scholar
• LaPensee EW, Schwemberger SJ, LaPensee CR, Bahassi el M, Afton SE, Ben-Jonathan N. Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Carcinogenesis 2009;30:1298–1304.
   PubMed Web of Science ®Google Scholar
• LaPensee EW, Ben-Jonathan N. Novel roles of prolactin and estrogens in breast cancer: resistance to chemotherapy. Endocr Relat Cancer 2010;17:91–107.
   Google Scholar
• Favy DA, Rio P, Maurizis JC, Hizel C, Bignon YJ, Bernard-Gallon DJ. Prolactin–dependent upregulation of BRCA1 expression in human breast cancer cell lines. Biochem Byophys Res Commun 1999;258:284–289.
   Google Scholar
• Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, Ormandy CJ. Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions. Oncogene 2007;26:543–553.
   PubMedGoogle Scholar
• Varghese B, Swaminathan G, Plotnikov A, Tzimas C, Yang N, Rui H, Fuchs SY. Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation. Mol Endocrinol 2010;24:2356–2365.
   Google Scholar
• Cohen AD, Cohen Y, Maislos M, Buskila D. Prolactin serum level in patients with breast cancer. Isr Med Assoc J 2000;2:287–289.
   PubMed Web of Science ®Google Scholar
• Nicol M, Willis C, Yiangou C, Sinnett D, Shousha S. Relationship between serum prolactin levels and histology of benign and malignant breast lesions: A detailed study of 153 consecutive cases. Breast J 2002;8:281–285.
   PubMedGoogle Scholar
• Bhatavdekar JM, Patel DD, Sherbet GV, Giri DD, Karelia NH, Vora HH, Shah NG, et al. Prognostic significance of plasma prolactin in breast cancer: Comparison with the expression of c erb B-2 oncoprotein. Eur J Surg Oncol 1993;19:409–413.
   PubMedGoogle Scholar
• Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, et al. Prolactin serum levels and breast cancer: Relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer 2010;103:1097–1102.
   PubMed Web of Science ®Google Scholar
• Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology 1996;137:5456–5462.
   PubMed Web of Science ®Google Scholar
• Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004;23:1248–1255.
   PubMed Web of Science ®Google Scholar
• Ploszaj T, Motyl T, Orzechowski A, Zimowska W, Wareski P, Skierski J, Zwierzchowski L. Antiapoptotic action of prolactin is associated with up-regulation of Bcl-2 and down-regulation of Bax in HC11 mouse mammary epithelial cells. Apoptosis 1998;3:295–304.
   Google Scholar
• Bremer TM, Jacquemier J, Charafe-Jauffret E, Viens P, Birnbaum D, Linke SP. Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients. Int J Cancer 2009;124:896–904.
   Google Scholar
• Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, et al. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010;103:668–675.
   PubMed Web of Science ®Google Scholar
• Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008;8:153.
   PubMed Web of Science ®Google Scholar
• Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, Yuan C, et al. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet 2011;12:48.
   PubMed Web of Science ®Google Scholar
• Razmkhah M, Jaberipour M, Ghaderi A. Bcl-2 and Fas expressions correlate with proliferative specificity of adipose-derived stem cells (ASCs) in breast cancer. Immunol Invest 2011;40:290–298.
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629–634.
   PubMed Web of Science ®Google Scholar
• Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 1989;14:289–298.
   PubMedGoogle Scholar
• Di Carlo R, Faggiuolo R, Muccionli G, Ortega C, Di Carlo F, Costantini M, et al. Prognostic significance of prolactin receptor on overall survival of patients with early breast cáncer; a long-term. The Breast 1994;3:147–150.
   Google Scholar